Those using e-cigarettes were more likely to develop cataracts, and those receiving cataract surgery less likely to develop depression and anxiety.
|Articles|December 21, 2011
Insurer to Reward Patients for Finding Cheaper Care
Advertisement
Harvard Pilgrim Health Care plans to introduce a rewards program through which its Massachusetts members who have been given referrals will be asked to call a “clinical concierge’’ service that can direct them to hospitals or medical facilities that charge less for the same tests.
In return, they will receive a check from Harvard Pilgrim, ranging from $10 to $75.
The program, called SaveOn, is intended to help patients make smarter health care choices, according to Harvard Pilgrim, and to rein in the runaway prices of imaging tests and other procedures that have contributed to steadily rising premiums.
Read the full story at:
Source: The Boston Globe
Advertisement
Related to this article
The conference session featured updates on several clinical trials, including the BRUNELLO trial, for treatment of diabetic macular edema (DME).
An intraoperative indocyanine green (ICG) fluorescence imaging protocol in sarcoma surgery detected 14 of 15 positive margins vs 4 of 15 for surgeons, though its specificity was 41.7% vs 88.9%.
Panelists engaged in a debate regarding using complement inhibitors in geographic atrophy, gauging public sentiment with a deciding vote.
A session at AAO 2026 highlighted how big data and minimally invasive glaucoma surgery (MIGS) could be utilized to help patients receive peak care.
The opening session of AAO 2026 featured a keynote speech discussing how artificial intelligence (AI) will play a part in health care.
Incidence of diabetic macular edema and the need for glaucoma surgery were reduced after treatment with glucagon-like peptide-1 receptor agonists.
Medicaid expansion was associated with lower colorectal cancer mortality, with the largest reductions in Hispanic patients and stage IV disease.
Advertisement
Advertisement
Trending on AJMC
1
MASH Fibrosis, Not Resolution, Predicts Mortality: Zobair Younossi, MD
2
A New Mechanism for DME in the BRUNELLO Trial: Donald J. D’Amico, MD
3
FDA Approves Once-Monthly Subcutaneous Olanzapine for Schizophrenia
4
Using Complement Inhibitors in GA Comes With Pros and Cons
5